BioCentriq entered into a long-term lease agreement with National Business Parks for a state-of-the-art cell therapy manufacturing facility which will serve as its headquarters in Princeton. This Princeton location builds upon BioCentriq’s established presence in Newark, creating a regional manufacturing network.
The facility will include an immediate $12 million capital investment in facility upgrades, equipment, and business system enhancements, strengthening BioCentriq’s position in the growing cell therapy sector and enhancing its ability to provide comprehensive development, manufacture, and quality control service solutions in support of its customers’ entire product lifecycle.
Spanning approximately 60,000 sq. ft., the site features six independent ISO 7 cleanrooms, equipped with cutting-edge manufacturing technologies, including advanced bioreactors, automated cell processing systems, and scalable production platforms.
With a proven track record in cell therapy manufacturing, the site operates under current GMP regulatory standards and industry guidelines and offers 30,000 sq. ft. of expansion space to accommodate additional clinical and commercial-scale production capacity. This strategic investment will enable BioCentriq to meet the growing demand for innovative cell therapy solutions globally.
With its strategic capital investments and expanded infrastructure, BioCentriq will offer a full range of services, including technology transfer and new technology assessments, process and analytical development, GMP manufacturing, quality control lot release, and stability testing services.
By offering both standardized platform solutions and fully customizable services, including hybrid and person-in-plant operations, dedicated cleanroom capacity, and other flexible service arrangements, BioCentriq empowers its clients to advance innovative, personalized therapies with unparalleled precision and efficiency.
“Securing this facility marks a significant milestone in our growth and reinforces our mission to deliver high-quality, scalable manufacturing solutions for cell therapy innovators globally,” said Syed T. Husain, Chairman and CEO of BioCentriq. “This facility allows us to further support our clients in bringing life-changing therapies to patients and demonstrates our ongoing commitment to providing industry-leading manufacturing expertise.”
The capital investment is expected to be completed and the facility fully operational by Q2 2025, with manufacturing services available immediately thereafter.
